Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity

Clinical Rheumatology

Volumn 33, Issue 1, 2014, Pages 39-47

  Takahashi, Nobunori ^a   Kojima, Toshihisa ^a   Kaneko, Atsushi ^b   Kida, Daihei ^b   Hirano, Yuji ^c   Fujibayashi, Takayoshi ^d   Yabe, Yuichiro ^e   Takagi, Hideki ^f   Oguchi, Takeshi ^g   Miyake, Hiroyuki ^h   Kato, Takefumi ⁱ   Fukaya, Naoki ^j   Ishikawa, Hisato ^b   Hayashi, Masatoshi ^k   Tsuboi, Seiji ^l   Kanayama, Yasuhide ^m   Kato, Daizo ^a   Funahashi, Koji ^a   Matsubara, Hiroyuki ^a   Hattori, Yosuke ^a   Hanabayashi, Masahiro ^a   Hirabara, Shinya ^a   Terabe, Kenya ^a   Yoshioka, Yutaka ^a   Ishiguro, Naoki ^a   more..

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^e TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^f NAGOYA CENTRAL HOSPITAL   (Japan)

^g ANJO KOSEI HOSPITAL   (Japan)

^h Ichinomiya Municipal Hospital   (Japan)

ⁱ Kato Orthopedic Clinic   (Japan)

^j Toyota Kai Medical Corporation Kariya Toyota General Hospital   (Japan)

^k NAGANO RED CROSS HOSPITAL   (Japan)

^l Shizuoka Kosei Hospital   (Japan)

^m Department of Clinical Laboratory   (Japan)

more..

Author keywords

Abatacept; Adalimumab; High disease activity; Japanese multicenter registry system; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; TOCILIZUMAB;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE REGISTRY; DRUG EFFICACY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISOLONE; REGISTRIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84900117221     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2392-2     Document Type: Article

References (28)

1. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics R (2006) Predictors of response to anti- TNF-alpha therapy among patients with rheumatoid arthritis: results from the British society for rheumatology biologics register. Rheumatology 45(12):1558-1565. doi:10.1093/rheumatology/ kel149
2. van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, Zahora R, Pedersen R, MacPeek D, Wajdula J, Fatenejad S (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56(12):3928-3939. doi:10.1002/ art.23141
3. Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, TamaiM, Arima K, Ichinose K, KamachiM, Yamasaki S, Nakamura H, Nakashima M, Mizokami A, Goto A, Fukuda T, Matsuoka N, Ueki Y, Tsukada T, Migita K, Shoumura F, Kawabe Y, Shibatomi K, MineM, Ida H,Origuchi T, AoyagiK, Eguchi K (2009) Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod Rheumatol Jpn Rheum Assoc 19(5):488-492
4. TanakaY, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E,Nawata M, Kameda H, Iwata S, Amano K, Yamanaka H (2008) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol Jpn Rheum Assoc 18(2):146-152. doi:10.1007/s10165-008-0026-3
5. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert- Roth A (2011) Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70(5):755-759. doi:10.1136/ard.2010.139725
6. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud- Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144(12):865-876
7. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, Li T, Zhou X, Becker JC, Aranda R, Peterfy C, Genant HK (2011) Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3- year results from the AIM trial. Ann Rheum Dis 70(10):1826-1830. doi:10.1136/ard.2010.139345
8. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, DougadosM(2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, doubleblind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8): 1096-1103. doi:10.1136/ard.2007.080002
9. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC (2009) The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 68(11):1708-1714. doi:10.1136/ard.2008. 099218
10. Westhovens R, Robles M, Ximenes AC, Nayiager S,Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, ShergyW, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Helfrick R, Bathon J (2009) Clinical efficacy and safety of abatacept inmethotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68(12):1870-1877. doi:10.1136/ard.2008. 101121
11. Leffers HC, OstergaardM, Glintborg B,KroghNS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, JacobsenMS, Dreyer L, Hetland ML (2011) All departments of rheumatology in D (2011) efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 70(7):1216-1222. doi:10.1136/ard.2010. 140129
12. Takahashi N, Kojima T, Terabe K, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kato D, Funahashi K, Matsubara H, Hattori Y, HanabayashiM, Hirabara S, Yoshioka Y, Ishiguro N (2012) Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Mod Rheumatol Jpn Rheum Assoc. doi:10. 1007/s10165-012-0760-4
13. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, HayashiM, Kato D,Matsubara H, Fujibayashi T, Kojima M, Ishiguro N, TBC (2011) Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: tsurumai biologics communication registry (TBCR) study. Mod Rheumatol Jpn Rheum Assoc. doi:10.1007/s10165-011-0518-4
14. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saisho K, Shimada K, Tohma S (2007) Disease activity score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared withDAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 66(9):1221-1226. doi:10.1136/ard.2006.063834
15. van Gestel A, van Riel P (1996) American college of rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al. Arthritis Rheum 39(3):535-537
16. WeinblattME, SchiffM, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R (2012) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.37711
17. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A (2012) Tocilizumab (TCZ) Monotherapy is superior to adalimumab (ADA) Monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis 71(Suppl 3):152
18. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the south Swedish arthritis treatment group register. Rheumatology 47(4):495-499. doi:10.1093/rheumatology/ken002
19. Smolen JS, Aletaha D (2011) Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 63(1):43-52 doi:10.1002/art.27740
20. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, Kubo S, Saito K, Shidara K, Kimura N, Nagasawa H, Kameda H, Amano K, Yamanaka H (2012) Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol Jpn Rheum Association 22(3):327-338. doi:10.1007/ s10165-011-0516-6
21. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, Research in Active Rheumatoid Arthritis Study G (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46(7): 1191-1199. doi:10.1093/rheumatology/kem091
22. Kaneko A, Hirano Y, Fujibayashi T, Hattori Y, Terabe K, Kojima T, Ishiguro N (2012) Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Mod Rheumatol Jpn Rheum Assoc. doi:10.1007/s10165-012-0705-y
23. Yamanaka H, Tanaka Y, Inoue E, Hoshi D, Momohara S, Hanami K, Yunoue N, Saito K, Amano K, Kameda H, Takeuchi T (2011) Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol Jpn Rheum Assoc 21(2):122-133. doi:10.1007/s10165-010-0366-7
24. Yabe Y, Kojima T, Kaneko A, Asai N, Kobayakawa T, Ishiguro N (2012) A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the tsurumai biologics communication registry (TBCR) study. Mod Rheumatol Jpn Rheum Assoc. doi:10.1007/ s10165-012-0648-3
25. Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y (2010) Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol Jpn Rheum Assoc 20(4):343-352. doi:10.1007/s10165-010-0290-x
26. Bykerk VP, Ostor AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Stancati A, Sibilia J (2012) Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 71(12):1950-1954. doi:10.1136/annrheumdis- 2011-201087
27. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, CerinicMM,Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, group G (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 34(8):1670-1673
28. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, Sato E, Saito K, Kaneko Y, Fukuyo S, Kurasawa T, Hanami K, Kameda H, Yamanaka H (2011) Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients- REACTION 52-week study. Rheumatology 50(10):1908-1915. doi:10.1093/rheumatology/ker221